AAD 2004

Drug Profile

AAD 2004

Alternative Names: AAD-2004

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurotech Pharmaceuticals
  • Developer AmKor Pharma; GNT Pharma
  • Class Anti-inflammatories; Antidementias; Antiparkinsonians; Salicylates; Small molecules; Sulfonamides
  • Mechanism of Action Amyloid beta-protein inhibitors; Antioxidants; Free radical scavengers; Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Amyotrophic lateral sclerosis; Arthritis; Depressive disorders; Diabetes mellitus; Pancreatitis; Parkinson's disease
  • Preclinical Pain

Most Recent Events

  • 19 Oct 2016 AAD 2004 series have patent protection for the treatment of pain and inflammation (GNT Pharma website, October 2016)
  • 19 Oct 2016 GNT Pharma has patent protection for AAD 2004 in the EU, Canada, Japan, China and the US (GNT Pharma website; October 2016)
  • 19 Oct 2016 GNT Pharma plans a phase I/II trial in Alzheimer's disease (GNT Pharma website; October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top